Perlegen, 454 to study drug response

Perlegen Sciences and 454 Life Sciences (now owned by Roche) have teamed up to conduct large scale genetic re-sequencing in DNA samples collected from people with specific responses to an undisclosed class of drug. The companies hope to identify a specific genetic variation and create a test to administer to patients taking the drug that will determine what their response will be. "This study holds the promise to improve therapeutic outcomes for a vast number of patients," noted Bryan Walser, MD, CEO of Perlegen. Perlegen was a 2003 Fierce 15 company.

- check out the release on the deal

Related Articles:
Roche snares 454's sequencing tech in buyout. Report
454 makes big advance in sequencing technology. Report
Perlegen strikes collaboration deal with Genentech. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.